Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

1 in non-Hodgkin's lymphoma. Under a strategic alliance established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting research and development activities focused on the potential treatment of cancer. GSK has obtained an option for the joint development and commercialization of ispinesib and SB-743921, exercisable during a defined period. Cytokinetics and GSK are conducting collaborative research activities directed to the mitotic kinesin centromere-associated protein E (CENP-E). GSK-923295, a CENP-E inhibitor, is being developed under the strategic alliance by GSK. GSK is expected to begin clinical trials with GSK-923295 in 2007. All of these drug candidates have arisen from Cytokinetics research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, and cardiovascular disease. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the ?Act?). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to the expected initiation, timing, conduct, scope and results of Cytokinetics and its partners research and development programs, including initiation of clinical trials; anticipated dates of release of data from clinical trials; the potential benefits of Cytokinetics drug candidates and potential drug candidates, including the benefits of mitotic kinesin i
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:8/29/2014)... Research and Markets has announced ... Market & Pipeline Insight 2014" report to their ... prevent and eradicate the prevalence of cancer have achieved ... to low specificity, safety and large number of side ... better solution. It has been discovered that peptides can ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... GOLDEN, Colo., Nov. 9 ABR-Affinity,BioReagents, a leading ... again exhibit at Medica in Dusseldorf, Germany. ... with over 137,000,visitors expected from all parts of ... BioReagents. The exposure is global, and it is ...
... Nov. 9 This week, Dr. Fouad,Bachour, ... Hennepin County,Medical Center, presented results of a ... http://www.sessionsdailynews.com/tuesday.pdf ) meeting in Orlando showing,that alerting ... a heart attack,patient arrives improves door-to-balloon times ...
Cached Medicine Technology:ABR-Affinity BioReagents to Exhibit in the U.S. Pavilion at Medica, November 14 - 17, 2007 2Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients 2
(Date:9/1/2014)... Registration is now open for the 4th Annual ... to be held on Sunday, September 21, 2014. The event ... Meadow in Secaucus, New Jersey. All proceeds from the race ... to restoring a sense of self, restoring the family unit, ... families. , General registration is $30 with special pricing for ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 The Outlier ... with extended exclusive interview content from one of the ... Ingredients of Outliers: Women Game Changers . The title ... Outliers: Woman Game Changer Jenny McClendon . McClendon is ... and was formerly the star of WeTV show, Raising ...
(Date:9/1/2014)... Nevada (PRWEB) September 01, 2014 Beginning ... to over 3,000 medical professionals and 10,000 consumers for ... is a 5-day gathering of the nation’s top medical ... associated diseases or conditions. The week-long event contains more ... evidence-based scientific instruction available in the pain management field. ...
(Date:8/31/2014)... 2014 MYMOBILEUNI (MMU) strategy is ... media marketing tools access to digital, resources, courses, ... utilize all tools to reach and collaborate with ... multiple learning channels. , MMU, today announced the ... authoring tool that applies social networking concepts to ...
(Date:8/31/2014)... (PRWEB) September 01, 2014 GoDaddy, ... companies that provide VPS (Virtual Private Server) hosting, ... server computer into many servers, each of which ... someone’s own dedicated computer. Top10BestSEOHosting.com has recently compared ... these three companies are the best VPS hosting ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 3Health News:GoDaddy, IX Web Hosting and Bluehost Are Awarded As Hosting Experts by Top10BestSEOHosting.com 2
... Can Reveal Blockages Prior to Stroke, CLEVELAND, Oct. ... Kennedy had removed today, are a significant risk factor,for ... the life-threatening,condition. Doppler ultrasound screening is a successful tool ... a stroke and before death or,disability occurs. Life ...
... 12 ABR -- Affinity,BioReagents, a leading global ... website at http://www.bioreagents.com . Re-launched with ... several enhancements which combine to make the customer,s,experience ... to,Ken Wilczek, President of ABR, "We solicited feedback ...
... 50%, study found, , , FRIDAY, Oct. 12 (HealthDay News) -- ... once a week can increase your risk of developing asthma, ... are a direct cause of asthma, or simply a trigger ... this epidemiological study. , However, the European team involved in ...
... Omnicell, Inc.,(Nasdaq: OMCL ), a leading provider of system ... 18 to discuss the,company,s third quarter financial results. What: ... When: October 18, 2007, 2:30 p.m. PDT, ... officer ...
... TO COMMENT ON THE MARKET FORECAST FOR THE DRUG, ... Ph.D., analyst,at Decision Resources, is available to discuss the ... of Merck,s Isentress, the,first integrase inhibitor drug which blocks ... new cells. Integrase inhibitors are a novel class ...
... WARRENDALE, Pa., Oct. 12 Helping its,employees to live ... SAE,International. Recently, the American Heart Association (AHA) recognized,SAE for ... Fit Friendly Company, an honor,presented to only a handful ... What does it mean? In short, it means ...
Cached Medicine News:Health News:Asymptomatic Carotid Artery Blockage a Significant Stroke Risk 2Health News:ABR -- Affinity BioReagents Announces Launch of New Website 2Health News:Home Spray Cleaners Could Raise Asthma Risk 2Health News:Home Spray Cleaners Could Raise Asthma Risk 3Health News:Omnicell Schedules Third Quarter Earnings Call 2Health News:Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: